Skip to main content
Erschienen in: Diabetologia 6/2008

01.06.2008 | Article

Primarily non-surgical management of osteomyelitis of the foot in diabetes

verfasst von: F. L. Game, W. J. Jeffcoate

Erschienen in: Diabetologia | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We examined the use of surgery and assessed the response to non-surgical management of osteomyelitis of the foot in diabetic patients.

Methods

We reviewed the records of all patients presenting to a single specialist centre with osteomyelitis complicating a diabetic foot ulcer over a 5 year period. Details were extracted on antibiotic choice and treatment duration, hospital admission, incidence of minor and major amputation, and 12 month outcomes.

Results

There were 147 patients, with mean age 64.7 years (66% men). Of these, 26 (18%) were admitted to hospital at the time of presentation and managed with intravenous antibiotics; the remainder were managed with oral antibiotics as outpatients. Surgery was undertaken because of life- or limb-threatening infection, or failure to respond, in 34 (23%) patients (minor amputation 28, major amputation six patients). The remaining 113 were managed non-surgically. Remission was induced in 66 (58.4% of 113), while 35 (31%) had a relapse. Of those experiencing relapse, 27 (77%) achieved apparent arrest of the infection with a further course of antibiotics; six underwent minor and two underwent major amputation. Of all 113 whose infection was initially managed without surgery, apparent remission was achieved with antibiotics alone in 93 (82.3%).

Conclusions/interpretation

As these observations were made in an unselected case series, they give more insight into the respective roles of surgical and non-surgical management. The results confirm that although urgent surgery is indicated in some patients, non-surgical management of those without limb-threatening infection is associated with a high rate of apparent remission.
Literatur
1.
Zurück zum Zitat Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA (2006) Risk factors for foot infections in individuals with diabetes. Diabetes Care 29:1288–1293PubMedCrossRef Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA (2006) Risk factors for foot infections in individuals with diabetes. Diabetes Care 29:1288–1293PubMedCrossRef
2.
Zurück zum Zitat Lipsky BA (2004) A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20(Suppl 1): S68–S77PubMedCrossRef Lipsky BA (2004) A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20(Suppl 1): S68–S77PubMedCrossRef
3.
Zurück zum Zitat Lipsky BA, Berendt AR, Deery HG 2nd et al (2004) IDSA Guidelines: diagnosis and treatment of diabetic foot infections. Clin Inf Dis 39:885–910CrossRef Lipsky BA, Berendt AR, Deery HG 2nd et al (2004) IDSA Guidelines: diagnosis and treatment of diabetic foot infections. Clin Inf Dis 39:885–910CrossRef
4.
Zurück zum Zitat Berendt RA, Peters EJG, Bakker K et al (2008) Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. DOI 10.1002/dmrr.836 Berendt RA, Peters EJG, Bakker K et al (2008) Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. DOI 10.​1002/​dmrr.​836
5.
Zurück zum Zitat Henke PK, Blackburn SA, Wain RW et al (2005) Osteomyelitis of the foot and toe in adults is a surgical disease: conservative management worsens lower extremity salvage. Ann Surg 241:885–894PubMedCrossRef Henke PK, Blackburn SA, Wain RW et al (2005) Osteomyelitis of the foot and toe in adults is a surgical disease: conservative management worsens lower extremity salvage. Ann Surg 241:885–894PubMedCrossRef
6.
Zurück zum Zitat Jeffcoate WJ, Lipsky BA (2004) Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis 39(Suppl 2):S115–S122PubMedCrossRef Jeffcoate WJ, Lipsky BA (2004) Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis 39(Suppl 2):S115–S122PubMedCrossRef
7.
Zurück zum Zitat Embil JM, Rose G, Trepman E et al (2006) Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int 27:771–779PubMed Embil JM, Rose G, Trepman E et al (2006) Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int 27:771–779PubMed
8.
Zurück zum Zitat Treece KA, Macfarlane RM, Pound N, Game FL, Jeffcoate WJ (2004) Validation of a system of foot ulcer classification in diabetes mellitus. Diabet Med 21:987–991PubMedCrossRef Treece KA, Macfarlane RM, Pound N, Game FL, Jeffcoate WJ (2004) Validation of a system of foot ulcer classification in diabetes mellitus. Diabet Med 21:987–991PubMedCrossRef
10.
Zurück zum Zitat Bamberger DM, Daus GP, Gerding DN (1987) Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med 83:653–660PubMedCrossRef Bamberger DM, Daus GP, Gerding DN (1987) Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med 83:653–660PubMedCrossRef
11.
Zurück zum Zitat Nix DE, Cumbo TJ, Kuritsky P, Devito JM, Schentag JJ (1987) Oral ciprofloxacin in the treatment of serious soft tissue infection: efficacy, safety and pharmacokinetics. Am J Med 82(Suppl):146–215PubMed Nix DE, Cumbo TJ, Kuritsky P, Devito JM, Schentag JJ (1987) Oral ciprofloxacin in the treatment of serious soft tissue infection: efficacy, safety and pharmacokinetics. Am J Med 82(Suppl):146–215PubMed
12.
Zurück zum Zitat Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN (1989) Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus. Am J Med 86:801–807PubMedCrossRef Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN (1989) Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus. Am J Med 86:801–807PubMedCrossRef
13.
Zurück zum Zitat Ha Van G, Siney H, Danan JP, Sachon C, Grimaldi A (1996) Treatment of osteomyelitis in the diabetic foot. Contribution of conservative surgery. Diabetes Care 19:1257–1260PubMedCrossRef Ha Van G, Siney H, Danan JP, Sachon C, Grimaldi A (1996) Treatment of osteomyelitis in the diabetic foot. Contribution of conservative surgery. Diabetes Care 19:1257–1260PubMedCrossRef
14.
Zurück zum Zitat Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG, Jeffcoate WJ (1997) Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 14:487–490PubMedCrossRef Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG, Jeffcoate WJ (1997) Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 14:487–490PubMedCrossRef
15.
Zurück zum Zitat Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD (1999) Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med 159:851–856PubMedCrossRef Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD (1999) Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med 159:851–856PubMedCrossRef
16.
Zurück zum Zitat Eneroth M, Larsson J, Apelqvist J (1999) Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J Diabetes Complications 13:254–263CrossRef Eneroth M, Larsson J, Apelqvist J (1999) Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J Diabetes Complications 13:254–263CrossRef
17.
Zurück zum Zitat Senneville E, Yazdanpanah Y (2001) Cazaubiel M et al Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 48:927–930PubMedCrossRef Senneville E, Yazdanpanah Y (2001) Cazaubiel M et al Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 48:927–930PubMedCrossRef
18.
Zurück zum Zitat Yadlapalli N, Vaishnar A, Sheehan P (2002) Conservative management of diabetic foot ulcers complicated by osteomyelitis. Wounds 14:31–35 Yadlapalli N, Vaishnar A, Sheehan P (2002) Conservative management of diabetic foot ulcers complicated by osteomyelitis. Wounds 14:31–35
19.
Zurück zum Zitat Game FL, Jeffcoate WJ (2006) MRSA isolation from diabetic foot ulcers—does it affect healing and is the problem getting worse? (Abstract) Diabetes 55(Suppl 1):99–OR Game FL, Jeffcoate WJ (2006) MRSA isolation from diabetic foot ulcers—does it affect healing and is the problem getting worse? (Abstract) Diabetes 55(Suppl 1):99–OR
Metadaten
Titel
Primarily non-surgical management of osteomyelitis of the foot in diabetes
verfasst von
F. L. Game
W. J. Jeffcoate
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 6/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-0976-1

Weitere Artikel der Ausgabe 6/2008

Diabetologia 6/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.